NPCENeuroPace Inc
Surgical & Medical Instruments & Apparatus
- Revenue
- $100M
- 25% YoY
- Operating margin
- -16.3%
- 40% YoY
- EBITDA
- −$16M
- 25% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $46M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired11% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-450% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $45M | $46M | $65M | $80M | $100M | 25% |
| Operating income | −$24M | −$41M | −$27M | −$22M | −$16M | 25% |
| Net income | −$36M | −$47M | −$33M | −$27M | −$21M | 21% |
| Operating cash flow | −$25M | −$37M | −$20M | −$18M | −$11M | 39% |
| Capex | $384K | $603K | $173K | $306K | $332K | 8.5% |
| Stock-based comp | $4M | $8M | $10M | $10M | $11M | 7.8% |
| Buybacks | — | — | — | $0 | $50M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.